Status:
UNKNOWN
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment
Lead Sponsor:
Fudan University
Conditions:
Neuroendocrine Tumors
Metastases
Eligibility:
All Genders
18-80 years
Brief Summary
This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis ...
Detailed Description
system treatments of metastatic PanNET include SSA, sunitinib, mTOR inhibitor and chemotherapy. For patients achieved PR/SD after system treatment, resection of primary tumor and metastasis maybe a be...
Eligibility Criteria
Inclusion
- Biopsy-proven neuroendocrine tumor
- primary site in pancreas
- Advanced disease with lymph node or distant metastases (N1, M1) cannot undergoing cytoreduction by surgery/local ablative therapy at the diagnosis
- curative intent of all therapies possible
- ECOG 0-2
Exclusion
- Undifferentiated neuroendocrine carcinoma or mixed neuroendocrine carcinoma secondary tumor
- functioning NET or advanced carcinoid heart disease
- part of hereditary syndrome, such as MEN1, VHL
- do not willing to receive systemic treatment
- diagnosed with other cancer within 5 years
Key Trial Info
Start Date :
August 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 25 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04066322
Start Date
August 25 2019
End Date
July 25 2025
Last Update
September 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai Municipality, China, 200032